Efficacy of rabeprazole for the treatment of gastroesophageal reflux disease in a 7-day non-interventional trial

Abstract

Aim. To evaluate the efficacy of seven-day treatment with rabeprazole (Razo®) 20 mg once daily in patients with NERD and esophagitis based on monitoring the results of pH-impedancemetry of the stomach and esophagus and assessment of clinical symptoms. Materials and methods. Thirty patients with typical GERD manifestations were examined. The study included patients who underwent pH-impedancemetry, endoscopic examination, and were prescribed treatment with rabeprazole at a dose of 20 mg once a day. Clinical monitoring was performed during three visits: before treatment, after 3 days, and after 7 days of treatment. Control pH-impedancemetry was performed after 7 days of therapy. The third visit was the endpoint of the study. Results. After 7 days of treatment, the response rate for heartburn was 86.7% in the overall group of patients with GERD, 94.4% in those with NERD, and 75.0% in patients with esophagitis stage A and B. After 7 days of therapy with rabeprazole, we registered a significant decrease in the total number of refluxes (from 88 to 54; p0.001), the number of acid refluxes (from 53 to 22; p0.001), the DeMeester index (from 23.81 to 7.62; p0.001), and AET (from 7.54 to 2.01; p0.001) in the esophagus and an increase in the median daily pH (from 1.8 to 5.4; p0.001) and the time with pH4 in the stomach (from 2.57 hours and 10.7% up to 12.3 hours and 51.3%; p0.001). 7-day therapy with rabeprazole was accompanied by a significant improvement in GERD patients in all parameters of quality of life. 100% of patients with GERD rated their satisfaction with therapy as “good” and “very good”. Conclusion. As a result of 7-day therapy of patients with NERD and esophagitis with Razo® at a dose of 20 mg per day, an excellent clinical response was obtained, confirmed by a marked optimization of pH-impedancemetry parameters.